BayerA.S., BlumenkrantzM.J., MongomerieJZCandida peritonitis: Report of 22 cases and review of the English literature.Am J Med1976; 61: 832–840.
3.
OolperT., BennettW., JonesS.Peritonitis associated with chronic peritoneal dialysis: A diagnostic and therapeutic approach.Dial Transplant1978; 7: 1173–1178.
4.
KhannaR., OreopoulosD.O., VasSFungal peritonitis in patients undergoing chronic intermittent or continuous ambulatory peritoneal dialysis.Proc Eur Dial Transplant Assoc1980; 17: 291–296.
5.
ArfaniaD., EverettE.D., NolphK.D., RubinJ.Uncommon causes of peritonitis in patients undergoing peritoneal dialysis.Arch Intern Med1981; 141: 61–64.
6.
DrouhetE., BabinetP., ChapusotJ.P., KleinknechtD.5-Fluorocytosine in the treatment of candidiasis with acute renal insufficiency.Biomedicine1973; 19: 408–414.
SchonebeckJ.Studies on Candida infection of the urinary tract and on the antimycotic drug 5-fluorocytosine.Scand J Urol Nephrol (Suppl II)1972; 6: 35–48.
9.
CutlerR.E., BlairA.D., KellyM.R.F1ucytosine kinetics in subjects with normal and impaired renal function.Clin Pharmacol Ther1978; 24: 333–341.
10.
BlockE.R., BennettJ.E., LivotiLOF1ucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance.Ann Intern Med1974; 80: 613–617.
11.
ShadomyS.Espinel-Ingroff A. Susceptibility testing of antifungal agents. In: Manual of Clinical Microbiology; Second Edition. Washington, D.C.1974: 569–574.
12.
HaleyL.Bioassay of antifungal agents in serum. In: Laboratory Methods Medical Mycology.Washington D.C.U.S. Department of Health, Education and Welfare, PHS No. 788361; 1978: 173–183.
13.
MedoffO., KobayashiO.S.Strategies in the treatment of systemic funal infections.N Engl J Med1980; 302: 145155.
